# DESCRIPTION

## FIELD OF THE INVENTION

- define invention scope

## BACKGROUND OF THE INVENTION

- discuss glaucoma and astrocytes

## SUMMARY OF THE INVENTION

- summarize invention methods

## DETAILED DESCRIPTION OF THE INVENTION

- introduce background of neurodegenerative diseases
- describe role of pro-inflammatory microglia, macrophages, and A1 astrocytes in glaucoma
- discuss links between cytokines and glaucoma
- introduce glucagon-like peptide 1 receptor agonist NLY01
- describe use of NLY01 in reducing retinal inflammation and neuron death
- outline method for reducing production of IL-1α, TNF-α, and C1q
- describe method for reducing transformation of astrocytes to A1 neurotoxic phenotype
- outline method for reducing retinal ganglion cell death
- describe use of adenoviral vector with triple knockout of genes encoding IL-1α, TNF-α, and C1q
- provide definitions of terms used in the disclosure

### Pharmaceutical Compositions

- define pharmaceutical compositions
- describe carriers and their characteristics
- outline administration methods and formulations

### Effective Doses

- define therapeutically effective amount
- determine dosage ranges

## EXAMPLES

### Methods and Materials

- describe experimental model
- outline method details
- summarize enzyme-linked immunosorbent assays

### Elevated Intraocular Pressure Induces A1 Astrocyte Reactivity in the Retina

- describe effect of elevated intraocular pressure on astrocyte reactivity

### TNF-α, IL-1α, and C1q Contribute to Retinal Ganglion Cell Death Secondary to eIOP

- describe role of TNF-α, IL-1α, and C1q in retinal ganglion cell death

### Early Retinal Inflammation is Driven by CD11b+ CD11c+ Cells and Persists Beyond IOP Re-Normalization

- describe early retinal inflammation and its persistence

### NLY01, a GLP-1R Agonist, Reduces IL-1α, TNF-α, and C1q Production by CD11b+ CD11c+ and CD11b+ CD11c− Cells and Decreases A1 Astrocyte Activation During eIOP

- describe effect of NLY01 on IL-1α, TNF-α, and C1q production and A1 astrocyte activation

## Discussion

- introduce glaucoma disease
- motivate A1 reactive astrocytes
- describe microbead-induced ocular hypertension mouse model
- discuss role of CD11b+ CD11c+ cells
- summarize NLY01 treatment effects

## Limitations

- discuss limitations of RGC degeneration analysis

